Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study

Jorge E. Cortes, Michele Baccarani, François Guilhot, Brian Druker, Susan Branford, Dong Wook Kim, Fabrizio Pane, Ricardo Pasquini, Stuart L. Goldberg, Matt Kalaycio, Beatriz Moiraghi, Jacob M. Rowe, Elena Tothova, Carmino De Souza, Marc Rudoltz, Richard Yu, Tillmann Krahnke, Hagop M. Kantarjian, Jerald P. Radich, Timothy P. Hughes

Research output: Contribution to journalArticle

208 Citations (Scopus)

Abstract

Purpose: To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Patients and Methods: A total of 476 patients were randomly assigned 2:1 to imatinib 800 mg (n = 319) or 400 mg (n = 157) daily. The primary end point was the major molecular response (MMR) rate at 12 months. Results: At 12 months, differences in MMR and complete cytogenetic response (CCyR) rates were not statistically significant (MMR, 46% v 40%; P = .2035; CCyR, 70% v 66%; P = .3470). However, MMR occurred faster among patients randomly assigned to imatinib 800 mg/d, who had higher rates of MMR at 3 and 6 months compared with those in the imatinib 400-mg/d arm (P = .0035 by log-rank test). CCyR also occurred faster in the 800-mg/d arm (CCyR at 6 months, 57% v 45%; P = .0146). The most common adverse events were edema, gastrointestinal problems, and rash, and all were more common in patients in the 800-mg/d arm. Grades 3 to 4 hematologic toxicity also occurred more frequently in patients receiving imatinib 800 mg/d. Conclusion: MMR rates at 1 year were similar with imatinib 800 mg/d and 400 mg/d, but MMR and CCyR occurred earlier in patients treated with 800 mg/d. Continued follow-up is needed to determine the clinical significance of earlier responses on high-dose imatinib.

Original languageEnglish (US)
Pages (from-to)424-430
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number3
DOIs
StatePublished - Jan 20 2010
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Cytogenetics
Imatinib Mesylate
Exanthema
Edema
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points : Tyrosine kinase inhibitor optimization and selectivity study. / Cortes, Jorge E.; Baccarani, Michele; Guilhot, François; Druker, Brian; Branford, Susan; Kim, Dong Wook; Pane, Fabrizio; Pasquini, Ricardo; Goldberg, Stuart L.; Kalaycio, Matt; Moiraghi, Beatriz; Rowe, Jacob M.; Tothova, Elena; De Souza, Carmino; Rudoltz, Marc; Yu, Richard; Krahnke, Tillmann; Kantarjian, Hagop M.; Radich, Jerald P.; Hughes, Timothy P.

In: Journal of Clinical Oncology, Vol. 28, No. 3, 20.01.2010, p. 424-430.

Research output: Contribution to journalArticle

Cortes, JE, Baccarani, M, Guilhot, F, Druker, B, Branford, S, Kim, DW, Pane, F, Pasquini, R, Goldberg, SL, Kalaycio, M, Moiraghi, B, Rowe, JM, Tothova, E, De Souza, C, Rudoltz, M, Yu, R, Krahnke, T, Kantarjian, HM, Radich, JP & Hughes, TP 2010, 'Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study', Journal of Clinical Oncology, vol. 28, no. 3, pp. 424-430. https://doi.org/10.1200/JCO.2009.25.3724
Cortes, Jorge E. ; Baccarani, Michele ; Guilhot, François ; Druker, Brian ; Branford, Susan ; Kim, Dong Wook ; Pane, Fabrizio ; Pasquini, Ricardo ; Goldberg, Stuart L. ; Kalaycio, Matt ; Moiraghi, Beatriz ; Rowe, Jacob M. ; Tothova, Elena ; De Souza, Carmino ; Rudoltz, Marc ; Yu, Richard ; Krahnke, Tillmann ; Kantarjian, Hagop M. ; Radich, Jerald P. ; Hughes, Timothy P. / Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points : Tyrosine kinase inhibitor optimization and selectivity study. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 3. pp. 424-430.
@article{70b0a74b6d644597829ee5746f45084f,
title = "Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study",
abstract = "Purpose: To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Patients and Methods: A total of 476 patients were randomly assigned 2:1 to imatinib 800 mg (n = 319) or 400 mg (n = 157) daily. The primary end point was the major molecular response (MMR) rate at 12 months. Results: At 12 months, differences in MMR and complete cytogenetic response (CCyR) rates were not statistically significant (MMR, 46{\%} v 40{\%}; P = .2035; CCyR, 70{\%} v 66{\%}; P = .3470). However, MMR occurred faster among patients randomly assigned to imatinib 800 mg/d, who had higher rates of MMR at 3 and 6 months compared with those in the imatinib 400-mg/d arm (P = .0035 by log-rank test). CCyR also occurred faster in the 800-mg/d arm (CCyR at 6 months, 57{\%} v 45{\%}; P = .0146). The most common adverse events were edema, gastrointestinal problems, and rash, and all were more common in patients in the 800-mg/d arm. Grades 3 to 4 hematologic toxicity also occurred more frequently in patients receiving imatinib 800 mg/d. Conclusion: MMR rates at 1 year were similar with imatinib 800 mg/d and 400 mg/d, but MMR and CCyR occurred earlier in patients treated with 800 mg/d. Continued follow-up is needed to determine the clinical significance of earlier responses on high-dose imatinib.",
author = "Cortes, {Jorge E.} and Michele Baccarani and Fran{\cc}ois Guilhot and Brian Druker and Susan Branford and Kim, {Dong Wook} and Fabrizio Pane and Ricardo Pasquini and Goldberg, {Stuart L.} and Matt Kalaycio and Beatriz Moiraghi and Rowe, {Jacob M.} and Elena Tothova and {De Souza}, Carmino and Marc Rudoltz and Richard Yu and Tillmann Krahnke and Kantarjian, {Hagop M.} and Radich, {Jerald P.} and Hughes, {Timothy P.}",
year = "2010",
month = "1",
day = "20",
doi = "10.1200/JCO.2009.25.3724",
language = "English (US)",
volume = "28",
pages = "424--430",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points

T2 - Tyrosine kinase inhibitor optimization and selectivity study

AU - Cortes, Jorge E.

AU - Baccarani, Michele

AU - Guilhot, François

AU - Druker, Brian

AU - Branford, Susan

AU - Kim, Dong Wook

AU - Pane, Fabrizio

AU - Pasquini, Ricardo

AU - Goldberg, Stuart L.

AU - Kalaycio, Matt

AU - Moiraghi, Beatriz

AU - Rowe, Jacob M.

AU - Tothova, Elena

AU - De Souza, Carmino

AU - Rudoltz, Marc

AU - Yu, Richard

AU - Krahnke, Tillmann

AU - Kantarjian, Hagop M.

AU - Radich, Jerald P.

AU - Hughes, Timothy P.

PY - 2010/1/20

Y1 - 2010/1/20

N2 - Purpose: To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Patients and Methods: A total of 476 patients were randomly assigned 2:1 to imatinib 800 mg (n = 319) or 400 mg (n = 157) daily. The primary end point was the major molecular response (MMR) rate at 12 months. Results: At 12 months, differences in MMR and complete cytogenetic response (CCyR) rates were not statistically significant (MMR, 46% v 40%; P = .2035; CCyR, 70% v 66%; P = .3470). However, MMR occurred faster among patients randomly assigned to imatinib 800 mg/d, who had higher rates of MMR at 3 and 6 months compared with those in the imatinib 400-mg/d arm (P = .0035 by log-rank test). CCyR also occurred faster in the 800-mg/d arm (CCyR at 6 months, 57% v 45%; P = .0146). The most common adverse events were edema, gastrointestinal problems, and rash, and all were more common in patients in the 800-mg/d arm. Grades 3 to 4 hematologic toxicity also occurred more frequently in patients receiving imatinib 800 mg/d. Conclusion: MMR rates at 1 year were similar with imatinib 800 mg/d and 400 mg/d, but MMR and CCyR occurred earlier in patients treated with 800 mg/d. Continued follow-up is needed to determine the clinical significance of earlier responses on high-dose imatinib.

AB - Purpose: To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Patients and Methods: A total of 476 patients were randomly assigned 2:1 to imatinib 800 mg (n = 319) or 400 mg (n = 157) daily. The primary end point was the major molecular response (MMR) rate at 12 months. Results: At 12 months, differences in MMR and complete cytogenetic response (CCyR) rates were not statistically significant (MMR, 46% v 40%; P = .2035; CCyR, 70% v 66%; P = .3470). However, MMR occurred faster among patients randomly assigned to imatinib 800 mg/d, who had higher rates of MMR at 3 and 6 months compared with those in the imatinib 400-mg/d arm (P = .0035 by log-rank test). CCyR also occurred faster in the 800-mg/d arm (CCyR at 6 months, 57% v 45%; P = .0146). The most common adverse events were edema, gastrointestinal problems, and rash, and all were more common in patients in the 800-mg/d arm. Grades 3 to 4 hematologic toxicity also occurred more frequently in patients receiving imatinib 800 mg/d. Conclusion: MMR rates at 1 year were similar with imatinib 800 mg/d and 400 mg/d, but MMR and CCyR occurred earlier in patients treated with 800 mg/d. Continued follow-up is needed to determine the clinical significance of earlier responses on high-dose imatinib.

UR - http://www.scopus.com/inward/record.url?scp=75749105885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749105885&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.25.3724

DO - 10.1200/JCO.2009.25.3724

M3 - Article

C2 - 20008622

AN - SCOPUS:75749105885

VL - 28

SP - 424

EP - 430

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -